ABL1 and renal carcinoma: Nilotinib and sorafenib are drugs used to treat myelogenous leukemia and renal cancer respectively by inhibiting the tyrosine kinase activities of the oncoprotein BCR-Abl (nilotinib) or of vascular endothelial growth factor receptor and platelet-derived growth factor receptor (sorafenib).